CAR-GPC3 T Cells
CAR-GPC3 T Cells is a biological therapy with 7 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 3 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
0
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 1Trial Status & Enrollment
100.0%
3 of 3 finished
0.0%
0 ended early
2
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3
Chimeric Antigen Receptor T Cells Targeting Glypican-3
Clinical Trials (7)
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3
Chimeric Antigen Receptor T Cells Targeting Glypican-3
CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma
Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma
All 7 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 7